endometrial cancer
Conditions
Interventions
MRI-guided radiotherapy: A hypofractionated schedule (5x6Gy) with reduced margins will be given twice weekly, with adaptation of the radiotherapy plan before each fraction on the MR-Linac (a linear ac
Sponsors
Radboud Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Women aged 18 years or older with histologically proven carcinoma of the endometrium, treated with curative hysterectomy with or without bilateral salpingo-oophorectomy. All histologies may be included (endometrioid, clear cell carcinoma, de-/undifferentiated carcinoma, carcinosarcoma, other non-endometrioid)Candidate for adjuvant EBRT: FIGO IB grade 3 endometrioid carcinomaFIGO stage II endometrioid carcinomaFIGO stage IIIA-C1 endometrioid carcinomaFIGO IB-II clear cell carcinomaFIGO IA-III carcinosarcinomaPatients receiving adjuvant systemic therapy are eligible as these therapies will not be administered concurrentlyPatients receiving vaginal vault radiotherapy are eligibleCapable of giving informed consent
Exclusion criteria
Exclusion criteria: Contra-indications for MRI according to the guidelines of the local department of Radiology, inability to lay on a treatment table for 45-60 minutes or severe claustrofobiaWHO performance score > 2Presence of para-aortic lymph node metastases (FIGO stage IIIC2)Prior pelvic radiotherapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is acute gastrointestinal and genitourinary toxicity, scored by the Common Terminology Criteria Adverse Events version 5.0. Secondary endpoints are late gastrointestinal and genitourinary toxicity, quality of life and biochemical disease free survival (defined by the Phoenix consensus definition); disease-specific survival; overall survival and metastasis-free survival. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints are late gastrointestinal and genitourinary toxicity, quality of life and biochemical disease free survival (defined by the Phoenix consensus definition); disease-specific survival; overall survival and metastasis-free survival. | — |
Countries
Netherlands
Contacts
Public ContactC. Reijnen
Radboud Universitair Medisch Centrum
Outcome results
None listed